Tau imaging in neurodegenerative diseases
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Aggregated tau protein is a major neuropathological substrate central to the pathophysiology of neurodegenerative diseases such as Alzheimer's disease (AD), frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration and chronic traumatic encephalopathy. In AD, it has been shown that the density of hyperphosphorylated tau tangles correlates closely with neuronal dysfunction and cell death, unlike β-amyloid. Until now, diagnostic and pathologic information about tau deposition has only been available from invasive techniques such as brain biopsy or autopsy. The recent development of selective in-vivo tau PET imaging ligands including [(18)F]THK523, [(18)F]THK5117, [(18)F]THK5105 and [(18)F]THK5351, [(18)F]AV1451(T807) and [(11)C]PBB3 has provided information about the role of tau in the early phases of neurodegenerative diseases, and provided support for diagnosis, prognosis, and imaging biomarkers to track disease progression. Moreover, the spatial and longitudinal relationship of tau distribution compared with β - amyloid and other pathologies in these diseases can be mapped. In this review, we discuss the role of aggregated tau in tauopathies, the challenges posed in developing selective tau ligands as biomarkers, the state of development in tau tracers, and the new clinical information that has been uncovered, as well as the opportunities for improving diagnosis and designing clinical trials in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“Recent Aβ imaging studies support the Aβ cascade hypothesis to some extent [14], but it is now recognised that Aβ deposition alone cannot explain AD progression and pathogenesis.”
ResultTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“The ability of tau to bind to microtubules is also regulated by post-translational modification of the protein by phosphorylation, glycosylation, glycation, ubiquitination, sumoylation, and nitration [1, 6].”
BackgroundThe spectrum of disease in chronic traumatic encephalopathy
McKee, A. C., Stein, T. D., Nowinski, C. J., Stern, R. A., Daneshvar, D. H., Alvarez, V. E., Lee, H.-S., Hall, G., Wojtowicz, S. M., Baugh, C. M., et al. (2013) · Brain · doi:10.1093/brain/aws307 · Cited by 2,098
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 1×
“Furthermore, the offspring of transgenic mice expressing mutant tau crossed with mutant APP mice developed Aβ plaques at the same age, but had a significantly higher density of NFTs in the limbic system and cortex [23].”
BackgroundFormation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
Cited by
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
Boxer, A. L., Yu, J.-T., Golbe, L. I., Litvan, I., Lang, A. E., & Höglinger, G. U. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30157-6 · Cited by 485
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease
Maass, A., Landau, S., Baker, S. L., Horng, A., Lockhart, S. N., La Joie, R., Rabinovici, G. D., & Jagust, W. J. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.05.058 · Cited by 462
“The recent advent of tauspecific positron emission tomography (PET) tracers now allows assessment of regional tau load in the living human brain (Dani et al., 2016; Saint-Aubert et al., 2017; Villemagne et al., 2015), which will provide new insights into the etiology of AD, and help diagnostic accuracy, early detectio…”
BackgroundBuckley, R. F., Mormino, E. C., Rabin, J. S., Hohman, T. J., Landau, S., Hanseeuw, B. J., Jacobs, H. I. L., Papp, K. V., Amariglio, R. E., Properzi, M. J., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4693 · Cited by 373
Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
Whitwell, J. L., Höglinger, G. U., Antonini, A., Bordelon, Y., Boxer, A. L., Colosimo, C., van Eimeren, T., Golbe, L. I., Kassubek, J., Kurz, C., et al. (2017) · Movement Disorders · doi:10.1002/mds.27038 · Cited by 260
Rubenstein, R., Chang, B., Yue, J. K., Chiu, A., Winkler, E. A., Puccio, A. M., Diaz-Arrastia, R., Yuh, E. L., Mukherjee, P., Valadka, A. B., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0655 · Cited by 260
Brain imaging of neurovascular dysfunction in Alzheimer’s disease
Montagne, A., Nation, D. A., Pa, J., Sweeney, M. D., Toga, A. W., & Zlokovic, B. V. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1570-0 · Cited by 239
18 F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
Smith, R., Puschmann, A., Schöll, M., Ohlsson, T., van Swieten, J., Honer, M., Englund, E., & Hansson, O. (2016) · Brain · doi:10.1093/brain/aww163 · Cited by 168
“These tracers, along with PET tracers revealing extracellular plaques containing amyloid-b fibrils, will be essential for improving the early diagnosis of Alzheimer’s disease in clinical practice as well as in the evaluation of novel disease-modifying therapies (Dani et al., 2016).”
Background[18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy
Whitwell, J. L., Lowe, V. J., Tosakulwong, N., Weigand, S. D., Senjem, M. L., Schwarz, C. G., Spychalla, A. J., Petersen, R. C., Jack, C. R., & Josephs, K. A. (2017) · Movement Disorders · doi:10.1002/mds.26834 · Cited by 159
Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology
Smith, R., Wibom, M., Pawlik, D., Englund, E., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3692 · Cited by 111
Murugan, N. A., Nordberg, A., & Ågren, H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00093 · Cited by 92
“42) and (9-40) fibrils there are many core sites (the sites buried within fibril and surrounded by protein residues and exposed only to negligible amount of solvent) and surface sites(28) (the”
InfluentialGobbi, L. C., Knust, H., Körner, M., Honer, M., Czech, C., Belli, S., Muri, D., Edelmann, M. R., Hartung, T., Erbsmehl, I., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00632 · Cited by 89
Canu, E., Agosta, F., Mandic-Stojmenovic, G., Stojković, T., Stefanova, E., Inuggi, A., Imperiale, F., Copetti, M., Kostic, V. S., & Filippi, M. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.05.018 · Cited by 62
Gossye, H., Van Broeckhoven, C., & Engelborghs, S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00757 · Cited by 34
18F-Flortaucipir in TDP-43 associated frontotemporal dementia
Smith, R., Santillo, A. F., Waldö, M. L., Strandberg, O., Berron, D., Vestberg, S., van Westen, D., van Swieten, J., Honer, M., & Hansson, O. (2019) · Scientific Reports · doi:10.1038/s41598-019-42625-9 · Cited by 33
Synthesis and quality control of [18F]T807 for tau PET imaging
Holt, D. P., Ravert, H. T., & Dannals, R. F. (2016) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3425 · Cited by 28
Human iPSC Models in Drug Discovery: Opportunities and Challenges
Silva, M. C., Cross, A., Brandon, N. J., & Haggarty, S. J. (2017) · Comprehensive Medicinal Chemistry III · doi:10.1016/b978-0-12-409547-2.12284-x · Cited by 6
Metadata
- Authors
- Dani, M., Brooks, D. J., & Edison, P.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2015-11-16
- Volume
- 43
- Issue
- 6
- Pages
- 1139-1150
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2172650616
- Cited by
- 124
- References
- 27
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.